Evidence map›Paper›PMID 37760556›Full record

ArticleCancers2023

The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.

Silvia Mezi, Andrea Botticelli, Simone Scagnoli, Giulia Pomati, Giulia Fiscon, Federica De Galitiis, Francesca Romana Di Pietro, Sofia Verkhovskaia, Sasan Amirhassankhani, Simona Pisegna and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Silvia MeziDepartment of Radiological, Oncological, and Anatomopathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-4746-2678
Andrea BotticelliDepartment of Radiological, Oncological, and Anatomopathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Simone ScagnoliDepartment of Radiological, Oncological, and Anatomopathological Sciences, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-4943-5622
Giulia PomatiDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Giulia FisconDepartment of Computer, Control, and Management Engineering "Antonio Ruberti", Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-3354-8203
Federica De GalitiisIstituto Dermopatico dell'Immacolata, IDI-IRCCS, 00144 Rome, Italy.
Francesca Romana Di PietroIstituto Dermopatico dell'Immacolata, IDI-IRCCS, 00144 Rome, Italy.
Sofia VerkhovskaiaIstituto Dermopatico dell'Immacolata, IDI-IRCCS, 00144 Rome, Italy.
Sasan AmirhassankhaniDepartment of Urology, S. Orsola-Malpighi Hospital, University of Bologna, Via Palagi, 40126 Bologna, Italy.
Simona PisegnaDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Giovanna GentileDepartment of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, 00185 Rome, Italy.ORCID 0000-0001-8667-3094
Maurizio SimmacoDepartment of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, 00185 Rome, Italy.
Bjoern GohlkeStructural Bioinformatics Group, Institute for Physiology, Charité-University Medicine Berlin, 10117 Berlin, Germany.
Robert PreissnerStructural Bioinformatics Group, Institute for Physiology, Charité-University Medicine Berlin, 10117 Berlin, Germany.ORCID 0000-0002-2407-1087
Paolo MarchettiIstituto Dermopatico dell'Immacolata, IDI-IRCCS, 00144 Rome, Italy.ORCID 0000-0002-9064-8761
Sapienza University of Rome · ITIstituto Dermopatico dell'Immacolata · ITCharité - Universitätsmedizin Berlin · DEUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBRAF and MEK inhibition is a successful strategy in managing BRAF-mutant melanoma, even if the treatment-related toxicity is substantial. We analyzed the role of drug-drug interactions (DDI) on the toxicity profile of anti-BRAF/anti-MEK therapy.

methodsIn this multicenter, observational, and retrospective study, DDIs were assessed using Drug-PIN software (V 2/23). The association between the Drug-PIN continuous score or the Drug-PIN traffic light and the occurrence of treatment-related toxicities and oncological outcomes was evaluated.

resultsIn total, 177 patients with advanced BRAF-mutated melanoma undergoing BRAF/MEK targeted therapy were included. All grade toxicity was registered in 79% of patients. Cardiovascular toxicities occurred in 31 patients (17.5%). Further, 94 (55.9%) patients had comorbidities requiring specific pharmacological treatments. The median Drug-PIN score significantly increased when the target combination was added to the patient's home therapy (

conclusionsDDIs emerged as a critical issue for the risk of treatment-related cardiovascular toxicity. Our findings support the utility of DDI assessment in melanoma patients treated with BRAF/MEK inhibitors.

Indexed as

BRAF inhibitorsBRAF mutationcardiological toxicitydrug–drug interactionMEK inhibitorsmetastatic melanoma

Identifiers

PMID37760556
PMCPMC10526382
OpenAlexW4386837745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.